The record
| Class | nootropic |
|---|---|
| Also known as | - |
| Chain length | - |
| Molecular weight | 813.92 Da |
| Half-life | 12 hours |
| Route | - |
| Studied for | - |
| Research use | - |
| What has been shown | - |
| How it works | BDNF increase; Enkephalin modulation; Dopamine/serotonin regulation |
| Patent status | - |
| Regulatory status | - |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Nerve Support / Neuro-repair Environment (affection, 65%)
- Cognitive Enhancement / Focus (affection, 66%)
- Neuroprotection Signaling (affection, 51%)
- ADHD (illness, 60%)
- Alzheimer's disease (illness, 45%)
- Chronic inflammatory conditions (illness, 30%)
- Cognitive enhancement (illness, 33%)
- Diabetic neuropathy (illness, 30%)
- Neuropathic pain (illness, 30%)
- Sarcoidosis-associated small fiber neuropathy (illness, 30%)
- Stroke recovery (illness, 52%)
- Traumatic brain injury (illness, 52%)
- Vascular dementia (illness, 45%)
- Low mood (symptom, 67%)
- Brain fog or poor focus (symptom, 50%)
- Memory lapses (symptom, 75%)